FBXL2 counteracts Grp94 to destabilize EGFR and inhibit EGFR-driven NSCLC growth

Abnormal activation of epidermal growth factor receptor (EGFR) drives non-small cell lung cancer (NSCLC) development. EGFR mutations-mediated resistance to tyrosine-kinase inhibitors (TKIs) is a major hurdle for NSCLC treatment. Here, we show that F-box protein FBXL2 targets EGFR and EGFR TKI-resist...

Descripción completa

Detalles Bibliográficos
Autores principales: Niu, Mengmeng, Xu, Jing, Liu, Yang, Li, Yuhuang, He, Tao, Ding, Liangping, He, Yajun, Yi, Yong, Li, Fengtian, Guo, Rongtian, Gao, Ya, Li, Rui, Li, Luping, Fu, Mengyuan, Hu, Qingyong, Luo, Yangkun, Zhang, Chunyan, Qin, Kewei, Yi, Jianqiao, Yu, Shuhan, Yang, Jian, Chen, Hu, Wang, Liang, Li, Zhonghan, Dong, Biao, Qi, Shiqian, Ouyang, Liang, Zhang, Yujun, Cao, Yang, Xiao, Zhi-Xiong Jim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8505509/
https://www.ncbi.nlm.nih.gov/pubmed/34635651
http://dx.doi.org/10.1038/s41467-021-26222-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8505509/
https://www.ncbi.nlm.nih.gov/pubmed/34635651
http://dx.doi.org/10.1038/s41467-021-26222-x

Ejemplares similares